Datum Källa Rubrik Typ Alternativ
2023-01-26 Iconovo Iconovo erhåller nytt europeiskt patent för sin engångsinhalator ICOone Analyser Ladda ner | Visa Stäng
2023-01-26 Iconovo Iconovo receives approval of new European patent for its single-use inhaler ICOone® Analyser Ladda ner | Visa Stäng
2023-01-17 Iconovo BioStock: Iconovo inleder 2023 med förhandlingar för ICOpre Pressreleaser Visa Stäng
2023-01-17 Iconovo BioStock: Iconovo starts 2023 with negotiations for ICOpre Pressreleaser Visa Stäng
2023-01-11 Iconovo Iconovo har inlett förhandlingar med ett globalt läkemedelsföretag om ett potentiellt licensavtal för sin inhalator ICOpre® Analyser Ladda ner | Visa Stäng
2022-12-15 Iconovo Iconovo utser Henrik Damkjær Simonsen till Chief Financial Officer Analyser Ladda ner | Visa Stäng
2022-12-15 Iconovo Iconovo appoints Henrik Damkjær Simonsen as Chief Financial Officer Analyser Ladda ner | Visa Stäng
2022-12-07 Iconovo Iconovo's ICOone® inhaler platform receives new patent approval in the US Analyser Ladda ner | Visa Stäng
2022-12-07 Iconovo Iconovos inhalatorplattform ICOone® erhåller nytt patentgodkännande i USA Analyser Ladda ner | Visa Stäng
2022-12-05 Iconovo BioStock: Iconovo satsar på läkemedelsförsäljning i Norden Pressreleaser Visa Stäng
2022-12-05 Iconovo BioStock: Iconovo establishes Nordic pharmaceutical sales Pressreleaser Visa Stäng
2022-11-16 Iconovo Iconovo utser Peter Åkerlund till tillförordnad CFO Analyser Ladda ner | Visa Stäng
2022-11-08 Iconovo Valberedning utsedd Iconovo Analyser Ladda ner | Visa Stäng
2022-11-08 Iconovo Nomination Committee appointed at Iconovo Analyser Ladda ner | Visa Stäng
2022-11-08 Iconovo BioStock: Iconovo reports Q3 and arranges pandemic event Pressreleaser Visa Stäng
2022-11-08 Iconovo BioStock: Iconovo rapporterar Q3 och arrangerar pandemievent Pressreleaser Visa Stäng
2022-11-04 Penser Access Penser Access: Intervju med Iconovo - Erik Penser Bank - 3 nov 2022 Analyser Visa Stäng
2022-11-03 Iconovo Abbreviated interim report 1 January - 30 September Analyser Ladda ner | Visa Stäng
Analyser | 3 Nov 2022 | Iconovo

Abbreviated interim report 1 January – 30 September

ICOone development supported by Bill & Melinda Gates Foundation

Significant events 1 July – 30 September
· Iconovo has received a grant of approximately SEK 9 million from the Bill & Melinda Gates Foundation to develop inhaled therapies based on ICOone Nasal for the next pandemic. The grant will be used to develop a low-cost product that enables the administration of medicinal substances to both the upper and lower respiratory tract. The project will run from August 2022 to June 2023. The aim is to establish a fast track for inhaled treatments that can improve global healthcare, particularly in low- and middle-income countries, in the event of a new viral pandemic. 

Significant events after the end of the third quarter
· Iconovo has conducted a study to assess the user friendliness of its ICOone Nasal inhaler. The aim is to make the ICOone Nasal so easy to use that anyone can operate it properly without detailed instructions.
 

Key figures for the Group, in TSEK unless otherwise indicated    Jul-Sep 2022 Jul-Sep 2021* Jan-Sep 2022 Jan-Sep 2021* Jan-Dec 2021*
Net turnover   7,205 6,169 17,082 11,809 15,409
Operating profit/loss   -10,077 -3,895 -31,772 -17,807 -26,513
Cash flow for the period   -15,453 60,741 -52,893 45,308 33,348
Earnings per share (SEK) before and after full dilution   -1.14 -0.43 -3.56 -2.15 -3.15
Cash and cash equivalents   42,144 106,997 42,144 106,997 95,037
Equity   105,828 145,667 105,828 145,667 137,034
Number of shares at period-end   8,847,500 8,847,500 8,847,500 8,847,500 8,847,500
No. of licensing agreements (royalty)**   6 6 6 6 6
No. of feasibility agreements**   1 1 1 1 2

 *Refers to the figures of the parent company, as there were none for the Group at the this time point.
**Number of agreements at the end of the period.

A WORD FROM THE CEO

We have taken significant steps towards realising the vision of ICOone – to replace drug injections with dry powder inhalation

This past quarter, Iconovo took a significant step toward its goal of establishing a fast track for inhalation therapies that can improve the ability of global healthcare to respond to a new viral pandemic. In July, the company received approximately SEK 9 million from the Bill & Melinda Gates Foundation for the development of a low-cost product that enables the administration of medicinal substances to both the upper and lower respiratory tract. The goal is to work together to develop products that can help people around the world, particularly in low-income countries, gain access to essential vaccines and drug therapies. The project is now in full swing and is expected to be completed by June 2023.
 
In the project, we will develop experimental models, perform characterisation work and invest in laboratory equipment to optimise our ICOone Nasal inhaler for inhalation therapy of viral respiratory infections. The project is a first step towards Iconovo’s vision of establishing a commercial-scale production platform that can be used to manufacture up to 100 million inhalers in a short period of time. We have already come a long way, but further investment from major international players with the same goal as Iconovo – to dramatically improve vaccine distribution in the next pandemic outbreak – is needed to take the technology to its full potential. Here it is important to seek strong partnerships with organisations willing to make major investments to drive technological change. The Bill & Melinda Gates Foundation is a perfect partner for us in this work.
 
ICOone-based COVID-19 vaccine
Most of the pieces are now in place for the next step in the development of our business partner ISR’s ICOone-based COVID-19 vaccine. The application to start a Phase I/II clinical trial in Bangladesh has been approved and an agreement has been signed for large-scale production of ICOone with the reputable German contract manufacturer Gerresheimer. In addition, an agreement securing the production of dry powder for a Phase III clinical trial and commercial launch has been signed with Catalent.
 
ICOpre moving forward in the sales process
During the summer and autumn, we attended several international congresses and met with companies that have shown great interest in our products being developed in the ICOpre inhaler. These discussions are continuing, and the aim is to identify a strong partner and to make an agreement for the further development and commercialisation of a portfolio of products based on ICOpre.
 
Handover of the CFO position
As previously announced, Anna Gallon, who has contributed greatly to the company’s development during her tenure as Chief Financial Officer, will be leaving her position shortly. The process of recruiting a successor is nearing its final stages, and we therefore see good prospects for a quick and smooth handover.
 
Pre-study with TOA Pharmaceuticals completed
During the quarter, we completed a pre-study in collaboration with the Japanese pharmaceutical company TOA Pharmaceuticals for the development of an inhaler for a generic version of a drug with significant sales in the Japanese market. During the year, the project generated revenues for Iconovo totalling approximately SEK 2 million. TOA Pharmaceuticals, in consultation with Iconovo, has decided not to proceed with the project evaluated during the pre-study. The companies will continue the established dialogue on potential new business opportunities.
 
New opportunities in new laboratories
The expansion of Iconovo’s laboratories is now complete, providing our formulation lab with even greater capacity and the ability to fully control humidity during powder development. This allows us to simulate the conditions that prevail in different geographical areas and ensure that our inhalers work well in the environments in which they will be used.
 
We are continuing to build for the future
Iconovo’s cash position at the end of the quarter was approximately SEK 42 million, giving us a good foundation on which to stand as we continue our efforts to attract more business and seize strategic opportunities. Right now, we are primarily doing this by investing in the value chain for ICOone and ICOcap. The establishment of our subsidiary Iconovo Pharma is also a key focus area. We are continuing to build an organisation that can take responsibility for the Nordic marketing of future products developed in collaboration with our partners. We are also evaluating opportunities to in-licence other commercially interesting drugs.

Johan Wäborg
CEO

2022-10-31 Penser Access Penser Access: Leverans av nya avtal på väg - Iconovo Analyser Visa Stäng
2022-10-28 Iconovo DELÅRSRAPPORT 1 JANUARI – 30 SEPTEMBER 2022 Analyser Ladda ner | Visa Stäng
2022-10-24 Iconovo BioStock: Founder and CTO on Iconovo's journey Pressreleaser Visa Stäng
2022-10-24 Iconovo BioStock: Iconovos grundare och CTO om bolagets resa Pressreleaser Visa Stäng
2022-10-24 Iconovo Iconovo's unique single dose inhaler ICOone® Nasal received high marks in user study Analyser Ladda ner | Visa Stäng
2022-10-24 Iconovo Iconovos unika engångsinhalator ICOone® Nasal erhöll goda omdömen i användarstudie Analyser Ladda ner | Visa Stäng
2022-08-12 Iconovo Iconovos Chief Financial Officer kommer att lämna bolaget under fjärde kvartalet 2022 Analyser Ladda ner | Visa Stäng
2022-08-12 Iconovo BioStock: Iconovos vd om anslaget från Bill & Melinda Gates Foundation Pressreleaser Visa Stäng
2022-07-26 Iconovo Iconovo får 9 MSEK i anslag från ansedd internationell stiftelse för att utveckla inhalerade terapier baserade på ICOone Nasal inför nästa pandemi Analyser Ladda ner | Visa Stäng
2022-07-26 Iconovo Iconovo receives USD 883,800 grant from recognized international foundation to develop inhaled therapy with ICOone Nasal for the next pandemic Analyser Ladda ner | Visa Stäng
2022-07-18 Iconovo Abbreviated interim report 1 January - 30 June 2022 Analyser Ladda ner | Visa Stäng
2022-07-15 Penser Access Penser Access: Q2-rapport andas optimism - Iconovo Analyser Visa Stäng
2022-07-15 Iconovo Delårsrapport 1 januari - 30 juni 2022 Analyser Ladda ner | Visa Stäng
2022-06-20 Iconovo BioStock: Iconovo höjer ribban i sina finansiella mål Pressreleaser Visa Stäng
2022-06-16 Penser Access Penser Access: Dags för djup inandning - Iconovo Analyser Visa Stäng
2022-06-13 Iconovo Iconovo receives approval of additional patent for ICOres® in the EU Analyser Ladda ner | Visa Stäng
2022-06-13 Iconovo Iconovo får ytterligare patent godkänt för ICOres® i EU Analyser Ladda ner | Visa Stäng
2022-06-07 Iconovo First patent granted in Japan for Iconovo’s ICOone Analyser Ladda ner | Visa Stäng
2022-06-07 Iconovo Iconovo erhåller förhandsgodkännande av sitt första patent för ICOone® i Japan Analyser Ladda ner | Visa Stäng
2022-06-03 Iconovo Iconovo updates its long-term financial targets – expects strong revenue growth with a high margin Analyser Ladda ner | Visa Stäng
2022-06-01 Iconovo Iconovo uppdaterar sina långsiktiga finansiella mål – ser stark intäktsökning med hög marginal Analyser Ladda ner | Visa Stäng
2022-05-23 Iconovo Iconovos samarbetspartner ISR tecknar avtal med Gerresheimer för storskalig produktion av ICOone Nasal Analyser Ladda ner | Visa Stäng
2022-05-17 Iconovo Kommuniké från årsstämma i Iconovo AB (publ) Analyser Ladda ner | Visa Stäng
2022-05-05 Iconovo BioStock: Iconovo nätverkar på RDD i Orlando Pressreleaser Visa Stäng
2022-05-02 Iconovo Abbreviated interim report 1 January - 31 March 2022 Analyser Ladda ner | Visa Stäng
2022-05-02 Iconovo Iconovo inleder ett strategiskt samarbete med Galenica för utveckling av nya inhalationsläkemedel Analyser Ladda ner | Visa Stäng
2022-05-02 Iconovo Iconovo and Galenica enters a strategic collaboration for the development of new inhalation products Analyser Ladda ner | Visa Stäng
2022-04-29 Iconovo Delårsrapport 1 januari - 31 mars 2022 Analyser Ladda ner | Visa Stäng
2022-04-19 Iconovo ICONOVO AB PUBLICERAR ÅRSREDOVISNING FÖR 2021 Analyser Ladda ner | Visa Stäng
2022-04-12 Iconovo Kallelse till årsstämma i Iconovo AB Analyser Ladda ner | Visa Stäng
2022-04-01 Iconovo BioStock: Iconovo ser ökat intresse inom inhalationsområdet Pressreleaser Visa Stäng
2022-03-29 Iconovo Iconovo extends collaboration with ISR with an agreement worth 13.6 million Swedish kronor (SEK) Analyser Ladda ner | Visa Stäng

Kommande händelser

17 Feb 2023 | Bokslutskommuniké 2022
28 Apr 2023 | Kvartalsrapport 2023-Q1
22 May 2023 | Årsstämma 2022